Leonard Robinson, MD
Internal Medicine · Matteson, ILNPI 1225078264
Payments from drug & device makers
Across 432 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$998
- Lilly USA, LLC$827
- Novo Nordisk$696
- GSK$591
- AstraZeneca$551
- Boehringer Ingelheim$519
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,284100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 63 | $998 |
| Lilly USA, LLC | 56 | $827 |
| Novo Nordisk | 42 | $696 |
| GSK | 30 | $591 |
| AstraZeneca | 31 | $551 |
| Boehringer Ingelheim | 27 | $519 |
| Johnson & Johnson | 30 | $518 |
| Merck | 27 | $347 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $229 |
| AbbVie(2 entities) | 9 | $198 |
| Abbott | 10 | $197 |
| E.r. Squibb & Sons, L.L.C. | 9 | $194 |
| Dexcom, Inc. | 8 | $191 |
| Sanofi-aventis U.S. LLC | 13 | $156 |
| Sunovion Pharmaceuticals Inc. | 14 | $150 |
| Amarin Pharma, Inc. | 7 | $118 |
| Boston Scientific | 1 | $100 |
| Amgen(2 entities) | 5 | $95 |
| Bayer | 3 | $81 |
| Exact Sciences | 4 | $70 |
| Phathom Pharmaceuticals, Inc. | 3 | $56 |
| Kowa Pharmaceuticals America, Inc. | 3 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Dynavax Technologies Corporation | 2 | $46 |
| Novartis | 3 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Tactile Systems Technology Inc | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Edwards Lifesciences | 1 | $23 |
| Bausch Health US, LLC | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| Metuchen Pharmaceuticals | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- ELIQUIS$102
- OBTRYX$100
How this compares
$7,297 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 92 | $145,835 |
| EliquisApixaban | 135 | $122,191 |
| JardianceEmpagliflozin | 54 | $63,861 |
| TrulicityDulaglutide | 47 | $55,760 |
| JanuviaSitagliptin Phosphate | 44 | $52,051 |
| XareltoRivaroxaban | 18 | $29,116 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $23,343 |
| FarxigaDapagliflozin Propanediol | 24 | $22,575 |
| MounjaroTirzepatide | 21 | $21,682 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $18,528 |
| EntrestoSacubitril/Valsartan | 17 | $17,551 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $13,578 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $6,712 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $5,870 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $696 | $145,83592 claims |
| PfizerEliquis | $998 | $122,191135 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $827 | $77,44268 claims |
| MerckJanuvia, Janumet | $347 | $65,62860 claims |
| Boehringer IngelheimJardiance | $519 | $63,86154 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $591 | $41,87061 claims |
| Johnson & JohnsonXarelto | $518 | $29,11618 claims |
| AstraZenecaFarxiga, Symbicort | $551 | $27,47437 claims |
| NovartisEntresto | $39 | $17,55117 claims |
| AbbVieSynthroid | $198 | $1,73217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Matteson
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.